Clene to Present at Two Major Investor Conferences in October

Clene Inc. (NASDAQ: CLNN), a clinical-stage biopharmaceutical company specializing in treatments for neurodegenerative diseases, has announced its participation in two significant investor conferences this month. These presentations offer the company a platform to showcase its innovative approaches to improving mitochondrial health and protecting neuronal function, particularly in the treatment of amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS).

The first of these events is the 2024 Maxim Healthcare Virtual Summit, a three-day conference scheduled for October 15-17, 2024. Clene is set to deliver a virtual presentation on October 15 at 2:30 p.m. ET. Later in the month, the company will present at the ThinkEquity Conference 2024, taking place at the Mandarin Oriental Hotel in New York on October 30, 2024, with Clene's presentation scheduled for 3:30 p.m. ET.

These investor conferences provide Clene with crucial opportunities to communicate its progress and potential to the investment community. The company's focus on mitochondrial health and neuronal function protection represents a novel approach in the field of neurodegenerative disease treatment. Clene's lead investigational drug, CNM-Au8, is particularly noteworthy as it aims to improve central nervous system cell survival and function by targeting mitochondrial function and the NAD pathway while reducing oxidative stress.

The significance of Clene's participation in these conferences extends beyond the company itself. For investors and the broader medical community, these presentations offer insights into potential breakthroughs in treating debilitating conditions like ALS, Parkinson's disease, and MS. Given the growing prevalence of neurodegenerative diseases in aging populations worldwide, advancements in this field could have far-reaching implications for public health and quality of life for millions of patients.

Clene's presence at these investor conferences also underscores the increasing interest in biopharmaceutical companies focusing on neurological disorders. As the global burden of these diseases continues to grow, innovative treatments that can slow or halt disease progression are in high demand. Clene's approach, which targets fundamental cellular processes rather than just symptoms, represents a promising direction in neurodegenerative disease research.

For the biopharmaceutical industry, Clene's presentations may provide valuable insights into the challenges and opportunities in developing treatments for complex neurological conditions. The company's progress could potentially influence research directions and investment strategies in the neurodegenerative disease space.

As Clene prepares to share its latest developments with investors, the broader implications of its research and potential therapies remain a point of keen interest. The outcomes of these presentations could influence not only the company's market position but also the landscape of neurodegenerative disease treatment as a whole. Stakeholders across the healthcare and investment sectors will be watching closely to gauge the potential impact of Clene's innovative approaches on the future of neurological health care.